Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.

ABSTRACT: The accumulation of senescent cells has an important role in the phenotypical changes observed in ageing and in many age-related pathologies. Thus, the strategies designed to prevent these effects, collectively known as senotherapies, have a strong clinical potential. Senolytics are a type of senotherapy aimed at specifically eliminating senescent cells from tissues. Several small molecule compounds with senolytic properties have already been identified, but their specificity and range of action are variable. Because of this, potential novel senolytics are being actively investigated. Given the involvement of HDACs and the PI3K pathway in senescence, we hypothesized that the dual inhibitor CUDC-907, a drug already in clinical trials for its antineoplastic effects, could have senolytic effe

SUBMITTER: Al-Mansour F 

PROVIDER: S-EPMC10120895 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature